Form 4: Surrozen Director Christopher Chai Acquires Options in Company Stock

Director Christopher Chai acquired options to purchase 1,333 shares of Surrozen, Inc. stock at an exercise price of $6.50, vesting annually from May 14, 2026.

Summary

• On May 14, 2025, Christopher Chai, a director of Surrozen, Inc., acquired options to purchase 1,333 shares of the company's common stock.
• The exercise price of these options is $6.50.
• The options vest and become exercisable annually, starting on May 14, 2026, subject to continuous service as a director.
• The options expire on May 14, 2035.
• The transaction was reported on Form 4, filed with the SEC on May 15, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard compensation practice for a company director. The option grant itself is neither overwhelmingly positive nor negative.

Positives

• The acquisition of options by a director signals confidence in the company's future.

Future Outlook

The vesting schedule of the options is contingent upon Christopher Chai's continued service as a director.

Industry Context

This is a standard practice for compensating and incentivizing board members in publicly traded companies, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Option grants to directors are a common practice in the biotechnology industry, used to align director incentives with shareholder value creation.
• The vesting schedule and exercise price are typical for director compensation packages in similarly sized companies.
• Comparing Surrozen's director compensation structure with companies like BioNTech or Moderna would provide a broader context.

Stakeholder Impact

• The option grant aligns the director's interests with those of the shareholders, incentivizing value creation.

Key Dates

Keywords

Surrozen, SRZN, Christopher Chai, Director, Options, Stock Options, Beneficial Ownership, SEC Form 4